Inogen, Inc. (INGN)
NASDAQ: INGN · IEX Real-Time Price · USD
9.25
+0.22 (2.44%)
At close: Jul 19, 2024, 4:00 PM
9.35
+0.10 (1.08%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Inogen Revenue
Inogen had revenue of $321.52M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $78.03M with 8.12% year-over-year growth. In the year 2023, Inogen had annual revenue of $315.66M.
Revenue (ttm)
$321.52M
Revenue Growth
-12.87%
P/S Ratio
0.68
Revenue / Employee
$385,519
Employees
834
Market Cap
218.09M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 315.66M | -61.58M | -16.32% |
Dec 31, 2022 | 377.24M | 19.24M | 5.37% |
Dec 31, 2021 | 358.00M | 49.52M | 16.05% |
Dec 31, 2020 | 308.49M | -53.46M | -14.77% |
Dec 31, 2019 | 361.94M | 3.83M | 1.07% |
Dec 31, 2018 | 358.11M | 108.67M | 43.57% |
Dec 31, 2017 | 249.44M | 46.61M | 22.98% |
Dec 31, 2016 | 202.83M | 43.82M | 27.56% |
Dec 31, 2015 | 159.01M | 46.47M | 41.29% |
Dec 31, 2014 | 112.54M | 37.09M | 49.17% |
Dec 31, 2013 | 75.44M | 26.87M | 55.31% |
Dec 31, 2012 | 48.58M | 17.94M | 58.57% |
Dec 31, 2011 | 30.63M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
23andMe Holding Co. | 219.64M |
The Joint | 119.12M |
Butterfly Network | 68.08M |
Molecular Partners AG | 7.64M |
Abeona Therapeutics | 3.50M |
Shattuck Labs | 2.72M |
Century Therapeutics | 1.37M |
Actinium Pharmaceuticals | 81.00K |
INGN News
- 5 days ago - Inogen to Report Second Quarter 2024 Financial Results on August 6, 2024 - Business Wire
- 18 days ago - Inogen Strengthens Leadership Team with Appointment of New General Counsel and Executive Vice President, Business Development - Business Wire
- 6 weeks ago - Inogen Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Mortality and Increased Cost-Effectiveness Ratio - Business Wire
- 2 months ago - Inogen Announces First Quarter 2024 Financial Results - Business Wire
- 3 months ago - Inogen to Report First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 4 months ago - Inogen To Present at 23rd Annual Needham Virtual Healthcare Conference - Business Wire
- 4 months ago - Inogen, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 5 months ago - Inogen Announces Fourth Quarter and Full-Year 2023 Financial Results - Business Wire